Xie C - Search Results

1

Design, Synthesis and Pharmacological Evaluation of Novel Hsp90N-terminal Inhibitors Without Induction of Heat Shock Response.

Liu P, Chen X, Zhu J, Li B, Chen Z, Wang G, Sun H, Xu Z, Zhao Z, Zhou C, Xie C, Lou L, Zhu W. Liu P, et al. Among authors: xie c. ChemistryOpen. 2019 Mar 28;8(3):344-353. doi: 10.1002/open.201900055. eCollection 2019 Mar. ChemistryOpen. 2019. PMID: 30976475 Free PMC article.

2

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.

Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J, Lou L. Tian S, et al. Among authors: xie c. Cancer Sci. 2011 Jul;102(7):1374-80. doi: 10.1111/j.1349-7006.2011.01939.x. Epub 2011 May 9. Cancer Sci. 2011. PMID: 21443688 Free PMC article. Clinical Trial.

3

YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance.

Zhao H, Quan H, Xie C, Xu Y, Xie F, Hu Y, Lou L. Zhao H, et al. Among authors: xie f, xie c. Cancer Lett. 2012 Jan 1;314(1):54-62. doi: 10.1016/j.canlet.2011.09.013. Epub 2011 Sep 19. Cancer Lett. 2012. PMID: 21982683

4

A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.

Xie CY, Xu YP, Zhao HB, Lou LG. Xie CY, et al. Exp Hematol. 2012 May;40(5):386-92. doi: 10.1016/j.exphem.2012.01.010. Epub 2012 Jan 21. Exp Hematol. 2012. PMID: 22269115 Free article.

5

Synthesis and cytotoxicity of diam(m)ineplatinum(II) complexes with 2,2-bis(hydroxymethyl)malonate as the leaving group.

Xing Y, Lou L, Chen X, Ye Q, Xu Y, Xie C, Jiang J, Liu W. Xing Y, et al. Among authors: xie c. Bioorg Med Chem Lett. 2012 Mar 15;22(6):2239-41. doi: 10.1016/j.bmcl.2012.01.091. Epub 2012 Feb 2. Bioorg Med Chem Lett. 2012. PMID: 22357340

6

Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.

Xie CY, Xu YP, Jin W, Lou LG. Xie CY, et al. Anticancer Drugs. 2012 Aug;23(7):698-705. doi: 10.1097/CAD.0b013e328352cc10. Anticancer Drugs. 2012. PMID: 22441567

7

RON confers lapatinib resistance in HER2-positive breast cancer cells.

Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L. Wang Q, et al. Among authors: xie c. Cancer Lett. 2013 Oct 28;340(1):43-50. doi: 10.1016/j.canlet.2013.06.022. Epub 2013 Jun 27. Cancer Lett. 2013. PMID: 23811285

8

Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition.

Sun L, Quan H, Xie C, Wang L, Hu Y, Lou L. Sun L, et al. Among authors: xie c. PLoS One. 2014 Mar 5;9(3):e90627. doi: 10.1371/journal.pone.0090627. eCollection 2014. PLoS One. 2014. PMID: 24598942 Free PMC article.

9

Synthesis, anticancer activity and toxicity of a water-soluble 4S,5S-derivative of heptaplatin, cis-{Pt(II)[(4S,5S)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]·(3-hydroxyl-cyclobutane-1,1-dicarboxylate)}.

Liu W, Jiang J, Xie C, Hou S, Quan H, Ye Q, Lou L. Liu W, et al. Among authors: xie c. J Inorg Biochem. 2014 Nov;140:126-30. doi: 10.1016/j.jinorgbio.2014.07.013. Epub 2014 Jul 22. J Inorg Biochem. 2014. PMID: 25108185

10

NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations.

Zhao J, Quan H, Xie C, Lou L. Zhao J, et al. Among authors: xie c. Pharmacol Res Perspect. 2014 Jun;2(3):e00043. doi: 10.1002/prp2.43. Epub 2014 Apr 7. Pharmacol Res Perspect. 2014. PMID: 25505589 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,361 results

Search Page

Filters